Description
Science Discovery, Design and Optimization of Myricetin Encapsulated Nanostructured Lipid Carriers...- Ghuncha Ambrin and Bal Ram Singh
Type of study: Alzheimer’s disease is a form of dementia identified by impairment of cognitive functions by Aβ (amyloid b peptide of about 37-48 amino acids, that is a proteolytic product of amyloid precursor protein or APP), neurofibrillary tangles, phosphorylated tau and plaque depositions. Aβ are the main factors causing senile plaques in hippocampus and the neocortex as well as in the cerebrovascular. There are only limited treatments of neurodenerative diseases, and with increase life expectancy it is becoming a major social and economic burden in the society. Myricetin (MY) has been recognized as a potential therapeutic, playing a protective role in the treatment of neurodegenerative diseases like Alzhmeir’s disease (AD), Parkinson’s disease (PD), Huntington’s disease etc. Because of its hydrophobic nature, MY has low solubility in aqueous solution, that may in fact be responsible for its cellular toxicity. The study accessed the bioavailability of MY encapsulated nanostructured lipid carriers (MY-NLCs) in the brain. Cellular toxicity and internalization of MY-NLCs were performed with an in vitro model, using SHSY5Y neuroblastoma cells. Furthermore, the study also reports neuroprotective role of MY against Aβ induced cytotoxicity and prevents Aβ induced caspase-3 activation and apoptosis. The study demonstrated significant reduction of Aβ levels in the brain with MY treatment exhibiting marked improvement in memory recognition in Aβ1-42 induced AD rat model.
